| payload |
{"created_at":"2026-04-07T03:18:43.308 {"created_at":"2026-04-07T03:18:43.308311+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:45301c53f034bb9d","evidence_event_ids":["evt_b83ba4fe9566"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1766140/0001213900-26-040179.txt","as_of":"2026-04-07T03:18:43.308311+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1766140/0001213900-26-040179.txt","company":"Unicycive Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1766140/0001213900-26-040179.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_25960cb33ed9047d","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1766140/0001213900-26-040179.txt","content_type":"text/plain","enriched_at":"2026-04-07T08:18:29.285177+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1766140/0001213900-26-040179.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1766140/0001213900-26-040179.txt","source_event_id":"evt_b83ba4fe9566","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"1f1e2a985770511c","kind":"sec_filing","published_at":"20260406","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.9,"dates_mentioned":["2026-04-06"],"entities":[{"asset_class":"equity","name":"Unicycive Therapeutics, Inc.","relevance":"high","symbol":"UNCY","type":"company"}],"event_type":"other","information_gaps":["No details on the reason for the resignation beyond it not being a disagreement.","No prior state of the board composition provided."],"key_facts":["Filing date: April 6, 2026","Form type: 8-K","Director resigned: Gaurav Aggarwal","Resignation not due to disagreement"],"numeric_claims":[],"primary_claim":"Gaurav Aggarwal resigned from the Board of Directors of Unicycive Therapeutics, Inc. on April 6, 2026.","relevance_score":0.7,"sentiment":"neutral","source_quality":"high","summary":"Unicycive Therapeutics, Inc. filed an 8-K on April 6, 2026, reporting the resignation of director Gaurav Aggarwal, which was not due to any disagreement with the company.","topics":["SEC filing","corporate governance","director resignation"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 Unicycive Therapeutics, Inc. \u00b7 Filed 20260406","ticker":"UNCY","tickers":["UNCY"],"title":"UNCY filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1766140/0001213900-26-040179.txt"}}... |